Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?
Clinical Cancer Research, July 2022
Vivek Subbiah, Boyi Gan
Understanding metabolic dependencies and their therapeutic vulnerabilities are key to precision oncology. Malic enzyme1 (ME1) is frequently overexpressed in cancers with pro-tumorigenic effects. In contrast, consistent loss of ME1 expression in synovial sarcoma compared with other sarcomas indicates a unique ferroptosis liability for precision therapy in this form of cancer.
|Members of the public||17||47%|
|Practitioners (doctors, other healthcare professionals)||6||17%|
|Science communicators (journalists, bloggers, editors)||1||3%|